

CERTIFICATE OF MAILING 37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Jomnissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450, on the date below:

May 19, 2004 Date

Steven Highlander

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Thomas J. Kodadek

Serial No.: 09/780,575

Filed: February 9, 2001

For: SELECTION OF PEPTIDES WITH

ANTIBODY-LIKE PROPERTIES

Group Art Unit: 1639

Examiner: Bennett M. Celsa

Atty. Dkt. No.: UTSD:566US/SLH

RESPONSE TO RESTRICTION REQUIREMENT DATED MARCH 19, 2004

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Commissioner:

This paper is submitted in response to the Restriction Requirement dated March 19, 2004 for which the date for response was April 19, 2004.

A request for a one-month extension of time to respond is included herewith along with the required fee. This one-month extension will bring the due date to May 19, 2004, which is within the six-month statutory period. Should such request or fee be deficient or absent, consider this paragraph such a request and authorization to withdraw the appropriate fee under 37 C.F.R. §§ 1.16 to 1.21 from Fulbright & Jaworski L.L.P. Account No.: 50-1212/UTSD:566US/SLH.

In response to the restriction requirement which the Examiner imposed, Applicant elects, without traverse, to prosecute claims 1-15, 22-26 and 29-30, *i.e.*, the Group I claims.

In response to the election of species, applicants make the following elections:

A.	Target Peptide:	(ICS)	(claims 1-15, 22, 23, 29, 30;
			claims 1-15, 22, 29 and 30 are
			generic)
B.	1 st DNA Binding Domain:	(lambda repressor)	(claims 1-15, 22-26, 29 and 30;
			claims 1-4, 6-15, 22-26, 29 and 30
			are generic)
C.	Library Encoded Peptide:	LEBP	(claims 1-15, 22-26, 29 and 30; all
			claims 1-15, 22-26, 29 and 30 are
			generic)
D.	2 nd DNA Binding Domian:	(lambda repressor)	(claims 1-15, 22-26, 29 and 30;
			claims 1-4, 6-15, 22-26, 29 and 30
			are generic)
E.	Indicator Polypeptide:	(Bgal)	(claims 1-6, 7-15, 22-26, 29, 30;
			claims 1-6, 8-15, 22-26, 29, 30 are
			generic)
F.	Prokaryotic Operator Region	:(lacZ operator)	(claims 1-15, 22-26, 29 and 30;
			claims 1-4, 6-15, 22-26, 29 and 30
			are generic)
G.	3 rd Peptide:	?	?
H.	Stabilizing Interaction:	(cross-linking)	(claims 1-15, 22-26, 29 and 30;
			claims 1-15, 22-26, 29 and 30 are
			generic)

Applicants believe an election for G, third peptide, is not required as the elected claims do not recite such an element.

The Examiner is invited to contact the undersigned attorney at (512) 536-3184 with any questions, comments or suggestions relating to the referenced patent application.

Respectfully submitted,

Steven I. Highlander Reg. No. 37,642

Attorney for Applicant

FULBRIGHT & JAWORSKI L.L.P. 600 Congress Avenue, Suite 2400 Austin, Texas 78701 (512) 536-3184

Date:

May 19, 2004